June 4, 2020 / 10:21 PM / a month ago

BRIEF-Data Presented From Phase 1B Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology

June 4 (Reuters) - Nektar Therapeutics:

* DATA PRESENTED FROM PHASE 1B STUDY OF NKTR-358, A NOVEL T REGULATORY CELL STIMULATOR, AT ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2020)

* NEKTAR THERAPEUTICS - DATA SHOW THAT NKTR-358 WAS SAFE AND WELL TOLERATED IN PATIENTS WITH MILD-TO-MODERATE SLE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below